regenicin page header biomedical collagen polymer header

Regenicin, Inc., is a biotechnology company specializing in the development
of regenerative cell therapies to restore the health of damaged tissues and organs.


Regenicin is playing a critical role in the development of the therapeutic candidate, NovaDerm™, a cultured cell technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of severe burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days.

show stock information

January 18, 2017: Regenicin Reports 2016 Operating Results.
click to read article
November 17, 2016: Regenicin Signs Supplier Agreement with Pure Med Farma LLC to Provide Closed Herd Collagen for the Manufacturing of NovaDerm®. click to read article
November 1, 2016: Regenicin, Inc. Completes Successful Pre-IND Meeting with Food and Drug Administration (FDA) for its New Autologous Cultured Skin Substitute, NovaDerm® . click to read article